MEDIA RELEASE PR38108
SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its
Position as a Market Leader in Microbial Biopharmaceutical Contract Production
AMSTERDAM, February 2/ PRNewswire-AsiaNet/ --
SynCo Bio Partners B.V. today announced that it has signed two commercial manufacturing agreements
with an undisclosed US biopharmaceutical company. Under the contract, SynCo will provide both process
validation and GMP commercial manufacturing services to support the commercial launch of two
separate biopharmaceutical products onto the US market.
SynCo has commenced with preparations for the manufacture of conformance lots in advance of its client's
BLA filings, expected in late 2010, in anticipation of commercial manufacturing commencing in 2011.
The products are both recombinant proteins, to be produced in E. coli. These products will be manufactured
in SynCo's large-scale GMP facility and take the tally of marketed products manufactured at its Amsterdam
facilities to six, since SynCo's inception in 2000. SynCo has previously supported process development efforts
for both products; an excellent example of how SynCo supports its clients' biopharmaceutical development
programs from early stage to commercial supply.
Pierre Warffemius, CEO of SynCo Bio Partners said, "This news is a further example of how SynCo can
offer a viable long-term manufacturing choice to its clients. SynCo has grown steadily over the last ten years in
a
very competitive market. The foundation of this growth has been our ability to form strong and mutually
beneficial relationships with our clients. As a consequence, SynCo is one of few biopharmaceutical CMOs in
the world with a recognized track record in both clinical and commercial manufacturing, providing financial
stability that allows us to continuously invest in our facilities."
About SynCo Bio Partners B.V.
SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and
commercial production experience in mammalian and microbial systems. This experience has been acquired
by developing new production processes for a number of international clients and producing a wide variety of
vaccines, recombinant proteins and live bacterial products in our state-of-the-art, GMP-licensed facilities since
inception in 2000.
Focused solely on biopharmaceuticals, SynCo acts as a strategic, long-term partner delivering product on
time to the highest quality standards. SynCo's team is committed to exceeding customer expectations, taking
a truly collaborative approach to contract manufacturing.
SOURCE: SynCo Bio Partners B.V.
Translations:
NEWS 
